MedTrace Logo

Study of an Approved Drug in Patients With Asthma (0476-289)(COMPLETED)

NCT00092144 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2024-08-15

No results posted yet for this study

Summary

The purpose of this study is to assess the efficacy and safety of an approved drug on asthma symptoms in patients with chronic asthma which is also active during the allergy season.

Conditions

Interventions

DRUG

MK0476, montelukast sodium / Duration of Treatment: 4 weeks

DRUG

Comparator: placebo / Duration of Treatment: 4 weeks

Sponsors & Collaborators

  • Organon and Co

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-02-26
Primary Completion
2004-06-15
Completion
2004-06-15

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00092144 on ClinicalTrials.gov